Hematopoyetic and lymphoid tumors

Summary

The Haematopoietic and Lymphoid Tumours group studies various types of tumours of the blood, their characteristics and patient responses to treatment. The study of tumours originating in the bloodline includes lymphomas and leukaemia, which have a major impact at the populational level. The study of their origin and characteristics, as well as testing treatments for these tumours, involves creating laboratory models and studies with patients (clinical trials).

1397

Publications

all_-_peripherial_blood_-_diagnosis_-_01

Strategic lines

Selected Publications

Westin,JR;Oluwole,OO;Kersten,MJ;Miklos,DB;Perales,MA;Ghobadi,A;Rapoport,AP et al, Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma, N. Engl. J. Med., 2023;389(2):148-157, doi:10.1056/NEJMoa2301665
Cortellini,A;Tabernero,J;Mukherjee,U;Salazar,R;Sureda,A;Maluquer,C;Ferrante,D et al, SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry, Lancet Oncol., 2023;24(4):335-346, doi:10.1016/S1470-2045(23)00056-6
Zinzani,PL;Mayer,J;Flowers,CR;Bijou,F;De Oliveira,AC;Song,Y;Zhang,Q et al, ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma., J. Clin. Oncol., 2023;41(33):5107-5117, doi:10.1200/JCO.23.00775
Maggioni,G;Bersanelli,M;Travaglino,E;Pierola,AA;Kasprzak,A;Montserrat,AS;Sauta,E et al, A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study, Lancet Haematol., 2023;10(2):117-128, doi:10.1016/S2352-3026(22)00323-4
Dreger,P;Corradini,P;Gribben,JG;Glass,B;Jerkeman,M;Kersten,MJ;Morschhauser,F et al, CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach., Lancet Haematol., 2023;10(12):1006-1015, doi:10.1016/S2352-3026(23)00307-1

Selected Projects

2023-751-1. PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. REGENERON PHARMACEUTICAL, INC . Budget: 761.371,2€. 2023- . PI: Sureda Balari, Anna.
20ACL045. ENSAYO EN FASE 1 DESTINADO A EVALUAR LA SEGURIDAD, LOS PERFILES FARMACOCINÉTICOS Y LA EFICACIA DEL EDO-S101, UN NUEVO FÁRMACO ALQUILANTE DE FUSIÓN DE HDACI PARA EL TRATAMIENTO DE TUMORES HEMATOLÓGICOS MALIGNOS EN RECIDIVA O REFRACTARIOS. Mundipharma Pharmaceuticals, S.L.;MUNDIPHARMA RESEARCH LTD. Budget: 392.839,2€. 2020- . PI: Sureda Balari, Anna.
2023-323-1. Estudio de prueba de concepto de fase Ib/II, abierto y de confirmación de dosis de siremadlin en combinación con venetoclax más azacitidina en participantes adultos con LMA no aptos para quimioterapia y con una respuesta subóptima al tratamiento de primera línea con venetoclax más azacitidina, y en participantes con LMA de nuevo diagnóstico, no aptos para quimioterapia y que presenten características clínicas de alto riesgo. Novartis Farmacéutica, S.A.. Budget: 321.492€. 2023- . PI: Arnan Sangerman, Montserrat.
2024-011-1. AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA. Pfizer, Inc . Budget: 297.463,65€. 2023- . PI: Sureda Balari, Anna.
20ACL103. SAFETY AND EFFICACY OF GEN3009 (DUOHEXABODY®-CD37) IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA – A FIRST-IN-HUMAN, OPEN-LABEL, PHASE I/IIA DOSE ESCALATION TRIAL WITH DOSE EXPANSION COHORTS. IQVIA RDS Spain SL. Budget: 288.775€. 2020- . PI: Sureda Balari, Anna.